ARWR

Arrowhead Pharmaceuticals, Inc. develops therapies using its RNA interference (RNAi) technology to target genes associated with diseases. The company focuses on creating drug candidates for various conditions, with its TRiM™ platform designed to silence disease-causing genes. Arrowhead operates in the biopharmaceutical sector, conducting clinical trials for its products, including plozasiran (ARO-APOC3), aimed at treating severe hypertriglyceridemia. Its customer base includes healthcare providers and patients in need of novel therapeutic solutions.